Millington-Ward, S.; Palfi, A.; Shortall, C.; Finnegan, L.K.; Bargroff, E.; Post, I.J.M.; Maguire, J.; Irnaten, M.; O′Brien, C.; Kenna, P.F.;
et al. AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma. Int. J. Mol. Sci. 2024, 25, 8876.
https://doi.org/10.3390/ijms25168876
AMA Style
Millington-Ward S, Palfi A, Shortall C, Finnegan LK, Bargroff E, Post IJM, Maguire J, Irnaten M, O′Brien C, Kenna PF,
et al. AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma. International Journal of Molecular Sciences. 2024; 25(16):8876.
https://doi.org/10.3390/ijms25168876
Chicago/Turabian Style
Millington-Ward, Sophia, Arpad Palfi, Ciara Shortall, Laura K. Finnegan, Ethan Bargroff, Iris J. M. Post, John Maguire, Mustapha Irnaten, Colm O′Brien, Paul F. Kenna,
and et al. 2024. "AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma" International Journal of Molecular Sciences 25, no. 16: 8876.
https://doi.org/10.3390/ijms25168876
APA Style
Millington-Ward, S., Palfi, A., Shortall, C., Finnegan, L. K., Bargroff, E., Post, I. J. M., Maguire, J., Irnaten, M., O′Brien, C., Kenna, P. F., Chadderton, N., & Farrar, G. J.
(2024). AAV-NDI1 Therapy Provides Significant Benefit to Murine and Cellular Models of Glaucoma. International Journal of Molecular Sciences, 25(16), 8876.
https://doi.org/10.3390/ijms25168876
